People | April 29, 2026
NADMED Limited appoints James Lee as CEO to drive global expansion
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
Subscribe To Our Newsletter & Stay Updated
